Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Orthopaedic Surgery and Research
Published in: Journal of Orthopaedic Surgery and Research 1/2019

Open Access 01-12-2019 | osteosarcoma | Systematic review

Clinicopathological and prognostic value of hypoxia-inducible factor-1α in patients with bone tumor: a systematic review and meta-analysis

Authors: Deqing Luo, Hongyue Ren, Wenjiao Zhang, Hang Xian, Kejian Lian, Hui Liu

Published in: Journal of Orthopaedic Surgery and Research | Issue 1/2019

Login to get access

Abstract

Background

Recently, many studies have shown the role of hypoxia-inducible factor-1α (HIF-1α) expression in the outcome of bone tumor. However, the results remain inconclusive. It is necessary to carry out a meta-analysis of all the current available data to clarify the relationship between HIF-1α and survival or clinicopathological features of bone tumor.

Methods

PubMed, Cochrane Library, Web of Science, China National Knowledge Internet, and Wanfang databases were used to search the relationship between HIF-1α and bone tumor. Articles investigating clinicopathological and prognostic value of HIF-1α in bone tumor patients were enrolled in this meta-analysis. Overlapping articles, duplicate data, reviews, case reports, and letters without original data were excluded. The pooled risk ratios (RRs) and hazard ratios (HRs) were used to evaluate the clinicopathological and prognostic value of HIF-1α on bone tumor patients, respectively.

Results

A total of 28 studies including 1443 patients were included in this meta-analysis, which were involved in three different types of bone tumor including 3 chondrosarcomas, 2 giant cell tumors of bone, and 23 osteosarcomas. Our results showed that high expression levels of HIF-1α were associated with poorer OS (overall survival) (HR = 2.61, 95% CI 2.11–3.23, P <  0.001) and shorter DFS (disease-free survival) (HR = 2.02, 95% CI 1.41–2.89, P <  0.001) in bone tumor. In addition, this study also analyzed the role of HIF-1α expression in clinicopathological features, which were closely related with the severity of bone tumor, including differentiation, clinical stage, metastasis, and microvessel density. Our results indicated that HIF-1α overexpression was significantly associated with differentiation (RR = 1.56, 95% CI 1.00–2.43, P = 0.049), clinical stage (RR = 1.75, 95% CI 1.25–2.45, P = 0.001), metastasis (RR = 1.78, 95% CI 1.58–2.00, P <  0.001), and microvessel density (SMD = 2.34, 95% CI 1.35–3.34, P <  0.001) of bone tumor.

Conclusions

HIF-1α overexpression indicated an unfavorable factor for OS and DFS in bone tumor, suggesting that HIF-1α may serve as a potential prognostic marker for bone tumor.
Appendix
Available only for authorised users
Literature
1.
Eyre R, Feltbower RG, Mubwandarikwa E, Eden TO, McNally RJ. Epidemiology of bone tumours in children and young adults. Pediatr Blood Cancer. 2009;53(6):941–52.PubMedCrossRef
2.
Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;429:286–91.CrossRef
3.
Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–68.PubMedCrossRef
4.
Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320–9.PubMedCrossRef
5.
Bovee JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer. 2010;10(7):481–8.PubMedCrossRef
6.
7.
van den Berg H, Slaar A, Kroon HM, Taminiau AH, Hogendoorn P. Results of diagnostic review in pediatric bone tumors and tumorlike lesions. J Pediatr Orthop. 2008;28(5):561–4.PubMedCrossRef
8.
Cohen NA, Lai SY, Ziober AF, Ziober BL. Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope. 2004;114(3):418–23.PubMedCrossRef
9.
Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–7.PubMedCrossRef
10.
Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med. 1997;3(5):515–20.PubMedCrossRef
11.
12.
13.
Zhou J, Huang S, Wang L, et al. Clinical and prognostic significance of HIF-1alpha overexpression in oral squamous cell carcinoma: a meta-analysis. World J Surg Oncol. 2017;15(1):104.PubMedPubMedCentralCrossRef
14.
Sun G, Wang Y, Hu W. Correlation between HIF-1alpha expression and breast cancer risk: a meta-analysis. Breast J. 2014;20(2):213–5.PubMedCrossRef
15.
Zhang ZG, Zhang QN, Wang XH, Tian JH. Hypoxia-inducible factor 1 alpha (HIF-1alpha) as a prognostic indicator in patients with gastric tumors: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(7):4195–8.PubMedCrossRef
16.
Zheng SS, Chen XH, Yin X, Zhang BH. Prognostic significance of HIF-1alpha expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8(6):e65753.PubMedPubMedCentralCrossRef
17.
18.
Ouyang Y, Li H, Bu J, et al. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis. Int J Biol Markers. 2016;31(3):e229–34.PubMedCrossRef
19.
Ren HY, Zhang YH, Li HY, et al. Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis. Onco Targets Ther. 2016;9:1477–87.PubMedPubMedCentralCrossRef
20.
Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011;39(2):91–2.PubMedCrossRef
21.
Bao ZQ, Chai DM, Xiao YZ, Zhang CC, Wu M, Zhou JS. Clinical significance of vasculogenic mimicry and its relation with hypoxia inducible factor-1α in osteosarcoma. Chin J Histochem Cytochem. 2013;22(3):241–8.
22.
Boeuf S, Bovee JV, Lehner B, Hogendoorn PC, Richter W. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology. 2010;56(5):641–51.PubMedCrossRef
23.
Chen WL, Feng HJ, Li HG. Expression and significance of hypoxemia-inducible factor-1alpha in osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106(2):254–7.PubMedCrossRef
24.
Chen C, Zhou H, Wei F, et al. Increased levels of hypoxia-inducible factor-1alpha are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma. J Orthop Res. 2011;29(1):143–51.PubMedCrossRef
25.
Chen Y, Yang Y, Yuan Z, Wang C, Shi Y. Predicting chemosensitivity in osteosarcoma prior to chemotherapy: an investigational study of biomarkers with immunohistochemistry. Oncol Lett. 2012;3(5):1011–6.PubMedPubMedCentralCrossRef
26.
Geng YH, Wang CX, Chen PH. Expressions of Cox-2 and HIF-1α and their relationship with clinicopathologic characteristics of osteosarcoma. Chin J Tumor. 2008;28(5):427–30.
27.
Guan GF, Lu Y, Ma Q, Wen YH, Yang LJ, Qiu XC. Expressions of HIF - 1α and CXCR4 in osteosarcoma and the significance. Chin J Modern Oncol. 2014;05:1162–5.
28.
Guo M, Cai C, Zhao G, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1alpha activation in human osteosarcoma. PLoS One. 2014;9(3):e90518.PubMedPubMedCentralCrossRef
29.
Hu HJ. Expressions of HIF - 1α and MMP9 in osteosarcoma and the significance: Chinese master’s dissertation of central south university; 2009.
30.
Hu T, He N, Yang Y, et al. DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas. J Exp Clin Cancer Res. 2015;34(1):22–33.
31.
Kubo T, Sugita T, Shimose S, et al. Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Joint Surg Br. 2008;90(3):364–70.PubMedCrossRef
32.
Li GW. Expressions and correlation of HIF - 1α and VEGF in osteosarcoma. Chin J Henan Surg. 2012;18(1):23–5.
33.
Li TF. Expressions of HIF - 1α and PTEN in osteosarcoma and the significance: Chinese master’s dissertation of university of south China; 2015.
34.
Lian HX, Li YQ, Zhao M, Liu RJ. Relationship between HIF-1α,VEGF expression and angiogenesis in osteosarcoma. Hebei J Tradit Chin Med. 2013;09:1422–4.
35.
Luo B. Expressions of HIF-1α and VEGF in giant cell tumor of bone and their relationship with tumor angiogenesis. Modern Med Health. 2009;25(1):14–6.
36.
Ma Q, Guo JG. Expressions of c-myc and HIF-1α in osteosarcoma and their relationship with tumor angiogenesis. Shandong Med J. 2014;54(5):76–8.
37.
Mao WB, Shao ZW, Pei H, Qiong Q. Relationship between the expression of HIF-1α, iNOS and GLUT-1 and angiogenesis in osteosarcoma. China Oncol. 2007;17(1):46–49.
38.
Mizobuchi H, Garcia-Castellano JM, Philip S, Healey JH, Gorlick R. Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res. 2008;466(9):2052–9.PubMedPubMedCentralCrossRef
39.
El Naggar A, Clarkson P, Zhang F, et al. Expression and stability of hypoxia inducible factor 1alpha in osteosarcoma. Pediatr Blood Cancer. 2012;59(7):1215–22.PubMedCrossRef
40.
Qian JR. Expressions of HIF - 1α in osteosarcoma and the significance: Chinese master’s dissertation of Shandong university; 2007.
41.
Wang Y, Qiu JS, Qiao H, Liang HZ, Luo CQ, Wang R. Expression of hypoxia-inducible factor 1a, VEGF and p53 and their association with angiogenesis and prognosis in osteosarcoma. Chin J Clin Exp Pathol. 2004;02:182–6.
42.
Wang S, Ren T, Huang Y, et al. BMPR2 and HIF1-alpha overexpression in resected osteosarcoma correlates with distant metastasis and patient survival. Chin J Cancer Res. 2017;29(5):447–54.PubMedPubMedCentralCrossRef
43.
Wu SZ. Expression of hypoxia-inducible factor 1a, VEGF and CD105 and their association with angiogenesis in osteosarcoma: Chinese master’s dissertation of central south university; 2010.
44.
Yang QC, Zeng BF, Dong Y, et al. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol. 2007;37(2):127–34.PubMedCrossRef
45.
Yin L, Hu YH, Ru JY, Jiang JH, Wang YF. Expressions of hypoxia-inducible factor-1α and CD105 in osteosarcoma and their clinical significance. J Modern Oncol. 2010;05:975–8.
46.
Zeng CZ, Luo C, Yang Z, Wang L. Heparanase participates in the growth and invasion of human U-2OS osteosarcoma cells and its close relationship with hypoxia-inducible factor-1alpha in osteosarcoma. Neoplasma. 2010;57(6):562–71.CrossRef
47.
Zhao H, Wu Y, Chen Y, Liu H. Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma. Int J Clin Oncol. 2015;20(6):1233–43.PubMedCrossRef
48.
Zheng XG, Tian K. Expressions of HIF - 1α and PTEN in osteosarcoma and the significance. Contemp Med. 2009;15(10):73–4.
49.
Nepal M, Choi HJ, Choi BY, et al. Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1alpha. Eur J Pharmacol. 2012;691(1–3):28–37.PubMedCrossRef
50.
Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5.PubMed
51.
Hameiri-Grossman M, Porat-Klein A, Yaniv I, et al. The association between let-7, RAS and HIF-1alpha in Ewing sarcoma tumor growth. Oncotarget. 2015;6(32):33834–48.PubMedPubMedCentralCrossRef
52.
Aryee DN, Niedan S, Kauer M, et al. Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res. 2010;70(10):4015–23.PubMedPubMedCentralCrossRef
53.
54.
Guan G, Zhang Y, Lu Y, et al. The HIF-1alpha/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells. Cancer Lett. 2015;357(1):254–64.PubMedCrossRef
55.
Lin C, McGough R, Aswad B, Block JA, Terek R. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res. 2004;22(6):1175–81.PubMedCrossRef
56.
Chang Z, Huo L, Wu Y, Zhang P. HIF-1 alpha had pivotal effects on downregulation of miR-210 decreasing viability and inducing apoptosis in hypoxic chondrocytes. ScientificWorldJournal. 2014;2014:876363.PubMedPubMedCentral
Metadata
Title
Clinicopathological and prognostic value of hypoxia-inducible factor-1α in patients with bone tumor: a systematic review and meta-analysis
Authors
Deqing Luo
Hongyue Ren
Wenjiao Zhang
Hang Xian
Kejian Lian
Hui Liu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Orthopaedic Surgery and Research / Issue 1/2019
Electronic ISSN: 1749-799X
DOI
https://doi.org/10.1186/s13018-019-1101-5

Other articles of this Issue 1/2019

Journal of Orthopaedic Surgery and Research 1/2019 Go to the issue

Research article

In vivo dynamic motion characteristics of the lower lumbar spine: L4–5 lumbar degenerative disc diseases undergoing unilateral or bilateral pedicle screw fixation combined with TLIF

Research article

Clinical results and surgery tactics of spinal osteotomy for ankylosing spondylitis kyphosis: experience of 428 patients

Research article

Clinical outcomes and quality of life after total hip arthroplasty in adult patients with a history of infection of the hip in childhood: a mid-term follow-up study

Systematic review

Comparative efficacy and safety of different hemostatic methods in total hip arthroplasty: a network meta-analysis

Research article

3D planning and surgical navigation of clavicle osteosynthesis using adaptable patient-specific instruments

Research article

Clavicle hook plate versus distal clavicle locking plate for Neer type II distal clavicle fractures